Sicart Associates LLC Has $1.01 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Sicart Associates LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 28.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,187 shares of the company’s stock after selling 2,500 shares during the period. Sicart Associates LLC’s holdings in Johnson & Johnson were worth $1,011,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Price T Rowe Associates Inc. MD increased its position in shares of Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after acquiring an additional 3,912,430 shares in the last quarter. FMR LLC increased its position in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares in the last quarter. GQG Partners LLC increased its position in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in Johnson & Johnson by 37.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares in the last quarter. 67.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective for the company. Raymond James reduced their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Atlantic Securities reduced their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Finally, Sanford C. Bernstein reduced their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now directly owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the transaction, the executive vice president now owns 126,456 shares in the company, valued at approximately $22,354,891.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 233,611 shares of company stock valued at $40,960,735. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $168.31 on Wednesday. The firm has a fifty day moving average price of $175.98 and a two-hundred day moving average price of $171.06. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a market cap of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.23 by $0.12. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same period last year, the firm earned $2.13 EPS. The business’s quarterly revenue was down 4.4% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.